BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Amber Louw; Vasiliki Panou; Weronika Maria Szejniuk; Christos Meristoudis; Siaw Ming Chai; Chris van Vliet; Y. C. Gary Lee; Ian M. Dick; Tina Firth; Louise Andersen Lynggaard; Azadeh Birbaneh Asghari; Mogens Vyberg; Johnni Hansen; Jenette Creaney; Oluf Dimitri Røe

doi:10.1016/j.jtho.2022.04.008

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney^*, Oluf Dimitri Røe

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Original language	English
Journal	Journal of Thoracic Oncology
ISSN	1556-0864
DOIs	https://doi.org/10.1016/j.jtho.2022.04.008
Publication status	E-pub ahead of print - 27 Apr 2022

Bibliographical note

Keywords

BAP1
Chemotherapy
Pemetrexed
Pleural mesothelioma
Predictive biomarkers

Access to Document

10.1016/j.jtho.2022.04.008Licence: CC BY 4.0

Cite this

Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., Lee, Y. C. G., Dick, I. M., Firth, T., Lynggaard, L. A., Asghari, A. B., Vyberg, M., Hansen, J., Creaney, J., & Røe, O. D. (2022). BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2022.04.008

Louw, Amber ; Panou, Vasiliki ; Szejniuk, Weronika Maria ; Meristoudis, Christos ; Chai, Siaw Ming ; van Vliet, Chris ; Lee, Y. C. Gary ; Dick, Ian M. ; Firth, Tina ; Lynggaard, Louise Andersen ; Asghari, Azadeh Birbaneh ; Vyberg, Mogens ; Hansen, Johnni ; Creaney, Jenette ; Røe, Oluf Dimitri. / BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma : A validation study. In: Journal of Thoracic Oncology. 2022.

@article{c1a3ce97f58d414a8860abf15cc0f291,

title = "BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study",

keywords = "BAP1, Chemotherapy, Pemetrexed, Pleural mesothelioma, Predictive biomarkers",

author = "Amber Louw and Vasiliki Panou and Szejniuk, {Weronika Maria} and Christos Meristoudis and Chai, {Siaw Ming} and {van Vliet}, Chris and Lee, {Y. C. Gary} and Dick, {Ian M.} and Tina Firth and Lynggaard, {Louise Andersen} and Asghari, {Azadeh Birbaneh} and Mogens Vyberg and Johnni Hansen and Jenette Creaney and R{\o}e, {Oluf Dimitri}",

year = "2022",

month = apr,

day = "27",

doi = "10.1016/j.jtho.2022.04.008",

language = "English",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier",

}

Louw, A, Panou, V , Szejniuk, WM , Meristoudis, C, Chai, SM, van Vliet, C, Lee, YCG, Dick, IM, Firth, T, Lynggaard, LA , Asghari, AB , Vyberg, M, Hansen, J, Creaney, J & Røe, OD 2022, 'BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study', Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2022.04.008

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma : A validation study. / Louw, Amber; Panou, Vasiliki ; Szejniuk, Weronika Maria ; Meristoudis, Christos; Chai, Siaw Ming; van Vliet, Chris; Lee, Y. C. Gary; Dick, Ian M.; Firth, Tina; Lynggaard, Louise Andersen ; Asghari, Azadeh Birbaneh ; Vyberg, Mogens; Hansen, Johnni; Creaney, Jenette; Røe, Oluf Dimitri.

In: Journal of Thoracic Oncology, 27.04.2022.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma

T2 - A validation study

AU - Louw, Amber

AU - Panou, Vasiliki

AU - Szejniuk, Weronika Maria

AU - Meristoudis, Christos

AU - Chai, Siaw Ming

AU - van Vliet, Chris

AU - Lee, Y. C. Gary

AU - Dick, Ian M.

AU - Firth, Tina

AU - Lynggaard, Louise Andersen

AU - Asghari, Azadeh Birbaneh

AU - Vyberg, Mogens

AU - Hansen, Johnni

AU - Creaney, Jenette

AU - Røe, Oluf Dimitri

PY - 2022/4/27

Y1 - 2022/4/27

KW - BAP1

KW - Chemotherapy

KW - Pemetrexed

KW - Pleural mesothelioma

KW - Predictive biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85130555503&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2022.04.008

DO - 10.1016/j.jtho.2022.04.008

M3 - Journal article

C2 - 35489694

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

ER -

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this